Vimarsana
Biggest News Aggregation in the World

Page 25 - Roche Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roche Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roche Group Today - Breaking & Trending Today

Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury - Vimarsana News

Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the Company has submitted an...

BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda - Vimarsana News

BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

Set-up of first BioNTainer as high-tech manufacturing solution for mRNA medicines is a critical step in establishing a resilient vaccine ecosystem in Africa and future pandemic preparednessBioNTech...

BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda - Vimarsana News

BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

Set-up of first BioNTainer as high-tech manufacturing solution for mRNA medicines is a critical step in establishing a resilient vaccine ecosystem...

Investegate | Company Announcement - Vimarsana News

Investegate | Company Announcement

Investegate announcements from BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

Ranibizumab (Lucentis) Biosimilars Pipeline Review 2023: Information on Approved Drugs and Drug Candidates in Research and Development as Biosimilar Antibodies - Vimarsana News

Ranibizumab (Lucentis) Biosimilars Pipeline Review 2023: Information on Approved Drugs and Drug Candidates in Research and Development as Biosimilar Antibodies

/PRNewswire/ -- The "Ranibizumab (Lucentis) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides...